{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:38:26Z","timestamp":1784900306470,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T00:00:00Z","timestamp":1500336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1038\/nrurol.2017.115","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T17:27:25Z","timestamp":1500398845000},"page":"588-590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["STAMPEDE, LATITUDE and Fernand Labrie's legacy"],"prefix":"10.1038","volume":"14","author":[{"given":"Bertrand","family":"Tombal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"van Soest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,18]]},"reference":[{"key":"BFnrurol2017115_CR1","doi-asserted-by":"publisher","unstructured":"James, N. D.  et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. \n                    http:\/\/dx.doi.org\/10.1056\/NEJMoa1702900\n                    \n                   (2017).","DOI":"10.1056\/NEJMoa1702900"},{"key":"BFnrurol2017115_CR2","doi-asserted-by":"publisher","unstructured":"Fizazi, K.  et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. \n                    http:\/\/dx.doi.org\/10.1056\/NEJMoa1704174\n                    \n                   (2017).","DOI":"10.1056\/NEJMoa1704174"},{"key":"BFnrurol2017115_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/pros.2990040605","volume":"4","author":"F Labrie","year":"1983","unstructured":"Labrie, F.  et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 4, 579\u2013594 (1983).","journal-title":"Prostate"},{"key":"BFnrurol2017115_CR4","doi-asserted-by":"crossref","unstructured":"Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355, 1491\u20131498 (2000).","DOI":"10.1016\/S0140-6736(00)02163-2"},{"key":"BFnrurol2017115_CR5","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1002\/cncr.24395","volume":"115","author":"H Akaza","year":"2009","unstructured":"Akaza, H.  et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 115, 3437\u20133445 (2009).","journal-title":"Cancer"},{"key":"BFnrurol2017115_CR6","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","volume":"27","author":"G Attard","year":"2009","unstructured":"Attard, G.  et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742\u20133748 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2017115_CR7","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","volume":"26","author":"S Gillessen","year":"2015","unstructured":"Gillessen, S.  et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann. Oncol. 26, 1589\u20131604 (2015).","journal-title":"Ann. Oncol."},{"key":"BFnrurol2017115_CR8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney, C. J.  et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737\u2013746 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol2017115_CR9","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James, N. D.  et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387, 1163\u20131177 (2016).","journal-title":"Lancet"},{"key":"BFnrurol2017115_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","volume":"17","author":"CL Vale","year":"2016","unstructured":"Vale, C. L.  et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 17, 243\u2013256 (2016).","journal-title":"Lancet Oncol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2017.115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2017.115","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrurol.2017.115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2017.115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:17:55Z","timestamp":1684469875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2017.115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,18]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["BFnrurol2017115"],"URL":"https:\/\/doi.org\/10.1038\/nrurol.2017.115","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,18]]},"assertion":[{"value":"18 July 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.T. is an investigator and a paid advisor for Astellas, Bayer, Janssen, and Sanofi-Genzyme. R.J.v.S. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}